NASDAQ:CBAY - CymaBay Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.25 +0.06 (+0.49 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$12.25
Today's Range$12.01 - $12.35
52-Week Range$5.91 - $15.59
Volume304,516 shs
Average Volume975,223 shs
Market Capitalization$713.95 million
P/E Ratio-15.51
Dividend YieldN/A
Beta1.9
CymaBay Therapeutics logoCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications. It has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBAY
CUSIPN/A
Phone510-293-8800

Debt

Debt-to-Equity Ratio0.01
Current Ratio12.91
Quick Ratio12.91

Price-To-Earnings

Trailing P/E Ratio-15.51
Forward P/E Ratio-10.56
P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million
Price / Sales72.34
Cash FlowN/A
Price / CashN/A
Book Value$1.53 per share
Price / Book8.01

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-27,550,000.00
Net MarginsN/A
Return on Equity-37.39%
Return on Assets-32.54%

Miscellaneous

Employees26
Outstanding Shares59,050,000
Market Cap$713.95 million

CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc (NASDAQ:CBAY) announced its quarterly earnings results on Friday, August, 10th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.04. View CymaBay Therapeutics' Earnings History.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for CymaBay Therapeutics.

What price target have analysts set for CBAY?

9 Wall Street analysts have issued 1-year price targets for CymaBay Therapeutics' stock. Their forecasts range from $16.00 to $30.00. On average, they anticipate CymaBay Therapeutics' share price to reach $21.8750 in the next year. This suggests a possible upside of 78.6% from the stock's current price. View Analyst Price Targets for CymaBay Therapeutics.

What is the consensus analysts' recommendation for CymaBay Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CymaBay Therapeutics.

What are Wall Street analysts saying about CymaBay Therapeutics stock?

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, ": We reiterate the Overweight rating and 12-month PT of $16 for CBAY stock. We believe evidence provided thus far support the notion that seladelpar will become an important new agent for treating primary biliary cholangitis (PBC) by virtue of its potentially superior safety profile characterized by the lack of pruritus induction. Efficacy as a treatment for non-alcoholic steatohepatitis (NASH) would significantly increase the drug’s commercial potential and broaden interest in the company from other biopharma industry participants, in our view." (8/9/2018)
  • 2. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (7/10/2018)
  • 3. HC Wainwright analysts commented, "EASL; Phase 3 Initiation in 2H18 on Track; Affirm Buy Stock Data 03/27/2018 Price $12.00 Exchange NASDAQ Price Target $18.00 52-Week High $15.59 52-Week Low $3.16 Enterprise Value (M) $611.7 Market Cap (M) $702 Public Market Float (M) 19.5 Shares Outstanding (M) 58.5 3 Month Avg Volume 980,454 Short Interest (M) 2.59 Balance Sheet Metrics Cash (M) $97.2 Total Debt (M) $6.9 Total Cash/Share $1.66 Book Value/Share $2.16 Cash (M): Amount shown is as of December 31 and does not include the $135.5M net proceeds from the recent equity raise.. EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.29) (0.20) (0.21) 2Q (0.30) (0.31) (0.22) 3Q (0.25) (0.21) (0.25) 4Q (0.30) (0.11) (0.27) FY (1.14) (0.79) (0.95) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 0.0 4.8 0.0 2Q 0.0 0.0 0.0 3Q 0.0 0.0 0.0 4Q 0.0 5.2 0.0 FY 0.0 10.0 5.0 20 15 10 5 0 MAR- 17 J UL- 17 NOV- 17 MAR- 18 12 10 8 6 4 2 0 Vol." (3/28/2018)

Who are some of CymaBay Therapeutics' key competitors?

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the folowing people:
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 45)
  • Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 63)
  • Dr. Pol F. Boudes, Chief Medical Officer (Age 61)
  • Mr. Daniel Menold, VP of Fin. (Age 48)
  • Mr. Paul T. Quinlan, Gen. Counsel & Corp. Sec. (Age 55)

Has CymaBay Therapeutics been receiving favorable news coverage?

News stories about CBAY stock have been trending positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CymaBay Therapeutics earned a coverage optimism score of 0.28 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 48.98 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for CymaBay Therapeutics.

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (8.33%), BlackRock Inc. (6.90%), FMR LLC (4.11%), Boxer Capital LLC (3.55%), Eagle Asset Management Inc. (3.51%) and Citadel Advisors LLC (3.26%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Kurt Von Emster, Robert James Wills and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.

Which institutional investors are selling CymaBay Therapeutics stock?

CBAY stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Boxer Capital LLC, EAM Investors LLC, SCP Investment LP, DAFNA Capital Management LLC, Ardsley Advisory Partners, EAM Global Investors LLC and Nexthera Capital LP. Company insiders that have sold CymaBay Therapeutics company stock in the last year include Carl Goldfischer and Kurt Von Emster. View Insider Buying and Selling for CymaBay Therapeutics.

Which institutional investors are buying CymaBay Therapeutics stock?

CBAY stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Eagle Asset Management Inc., Carillon Tower Advisers Inc., Baker BROS. Advisors LP, Voya Investment Management LLC, Citadel Advisors LLC, Bank of New York Mellon Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Robert James Wills and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $12.25.

How big of a company is CymaBay Therapeutics?

CymaBay Therapeutics has a market capitalization of $713.95 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-27,550,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. CymaBay Therapeutics employs 26 workers across the globe.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7999 GATEWAY BLVD SUITE 130, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]


MarketBeat Community Rating for CymaBay Therapeutics (NASDAQ CBAY)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  466
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe CBAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.